Please login to the form below

Not currently logged in

AZ links with Abbott on personalised asthma diagnostic

Diagnostic would aim to identify patients most likely to respond to tralokinumab

abbot hq 

AstraZeneca (AZ) has teamed up with Abbott to develop a companion diagnostic for experimental asthma drug tralokinumab, currently in phase III testing.

To date there are no approved companion diagnostics for asthma therapies, according to AZ, which said the diagnostic would be able to identify patients most likely to respond to treatment with the drug.

Tralokinumab is an anti-interleukin-13 (IL-13) antibody - originally developed by AZ's Medimmune unit - that entered phase III testing last summer for patients with severe asthma that is inadequately controlled using corticosteroids and long-acting beta agonists.

IL-13 is thought to be intimately involved in the onset of asthma attacks, and elevated levels of the cytokine seem to tally with severe, frequent attacks and impaired lung function in asthma patients.

Abbott will develop a kit that will measure serum levels of the proteins periostin and DPP4, which are thought to be biomarkers that reveal when IL-13 activity has increased in patients with severe asthma. 

The tests will be used in AZ's phase III trials programme and so could be approved alongside tralokinumab if successful.

The latest deal is one of a pair of collaborations just announced by AZ, sitting alongside an agreement with the Montreal Heart Institute (MIH) that will try to find biomarkers for cardiovascular diseases and diabetes.

Bing Yao, head of the respiratory, inflammation and autoimmunity innovative medicines unit at MedImmune, said "we anticipate that physicians will ultimately use these tests to better identify patients likely to benefit most from tralokinumab to bring their condition under control." 

He added: "we are on the cusp of a new era in personalised healthcare, one which will see great improvements for patients treated with respiratory medicines."

Tralokinumab is one of several new drugs targeting IL subtypes that are coming through the pipeline for asthma and promise to provide another line of therapy for patients who cannot control symptoms using current treatments. 

The use of diagnostics to select patients most likely to benefit from therapy could potentially mean these drugs become first-line candidates in some cases.

Other pipeline candidates include AZ's IL-5 antagonist benralizumab which is in the latter stages of development. GlaxoSmithKline (GSK) is currently leading the IL-5 pack with its mepolizumab product - filed in Europe last November - while Teva has a candidate called reslizumab due for filing this year.

Regeneron and Sanofi have a dual IL-4 and IL-13 blocker called dupilumab in phase III, while AZ's IL-17-targeting brodalumab is scheduled to be filed for psoriasis later this year and is in a phase II study in inadequately controlled severe asthma.

Article by
Phil Taylor

14th May 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...